Fighting cancer with plant-expressed pharmaceuticals

Trends in Biotechnology

Volumn 25, Issue 10, 2007, Pages 455-459

  Pujol, Merardo ^a   Gavilondo, Jorge ^a   Ayala, Marta ^a   Rodríguez, Meilyn ^a   González, Ernesto M ^a   Pérez, Lincidio ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL CULTURE; BACTERIA; COST EFFECTIVENESS; DISEASES; DRUG PRODUCTS; DRUG THERAPY; YEAST;

BIOLOGICAL THERAPIES; CANCER DRUGS; MAMMALIAN CELLS; RECOMBINANT PHARMACEUTICALS;

ONCOLOGY;

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CETUXIMAB; NIMOTUZUMAB; PACLITAXEL; PLANT MEDICINAL PRODUCT; RITUXIMAB; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

CANCER; CANCER THERAPY; DRUG MANUFACTURE; GLYCOSYLATION; IMMUNOTHERAPY; MAMMAL CELL; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; YEAST CELL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; HUMANS; PLANT EXTRACTS; PLANTS, GENETICALLY MODIFIED; RECOMBINANT PROTEINS;

MAMMALIA;

EID: 34548819305     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2007.09.001     Document Type: Review

References (51)

1. Lollini P., et al. Vaccines for tumor prevention. Nat. Rev. Cancer 6 (2006) 204-216
2. Belsey M.J., and Pavlou A.K. Leading therapeutic recombinant protein sales forecast and analysis to 2010. Journal of Natural Biotechnology 12 (2005) 69-73
3. Pavlou A.K., and Reichert J.M. Recombinant protein therapeutics - success rates, market trends and values to 2010. Nature Biotechnology 22 (2004) 1513-1519
4. Lawrence S. Billion dollar babies - biotech drugs as blockbusters. Nat. Biotechnol. 25 (2007) 380-382
5. Berenson, A. (2006) A cancer drug shows promise, at a price that many can't pay. The New York Times 15 February
6. Pujol M., et al. State of plant-made pharmaceuticals sector 2005: setting healthy roots. Biotecnol. Apl. 22 (2005) 59-60
7. Twyman R.M., et al. Transgenic plants in the biopharmaceutical market. Expert Opin. Emerg. Drugs 10 (2005) 185-218
8. Raskin I., et al. Plants and human health in the twenty-first century. Trends Biotechnol. 20 (2002) 522-530
9. Swerdlow J.L. Nature's medicine: Plants that heal. HerbalGram 49 (2000) 44-51
10. Pierpoint W.S. Salicylic acid and its derivatives in plants: Medicines, metabolites and messenger molecules. Adv. Adv. Bot. Res. 20 (1994) 163-235
11. Cordell G.A. Biodiversity and drug discovery. Asymbiotic relationship. Phytochemistry 55 (2000) 463-480
12. Das, R.C. (2006) Antibody Therapeutics - Product Development, Market Trends, and Strategic Issues, Revised Edition, D&MD Publications
13. Hood E.E., et al. Monoclonal antibody manufacturing in transgenic plants - myths and realities. Curr. Opin. Biotechnol. 13 (2002) 630-635
14. Ko K., et al. Inhibition of tumor growth by plant-derived mAb. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7026-7030
15. Brodzik R., et al. Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 8804-8809
16. McCormick A.A., et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 703-708
17. Ludwig D.L., et al. Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed. Hum. Antibodies 13 (2004) 81-90
18. Rodríguez M., et al. Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor. Biotechnol. Bioeng. 89 (2005) 188-194
19. Crombet T., et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol. 22 (2004) 1646-1654
20. Allan D.G. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 10 (2005) 760-761
21. Vaquero C., et al. Transient expression of a tumor-specific single chain fragment and a chimeric antibody in tobacco leaves. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11128-11133
22. Vaquero C., et al. A carcinoembryonic antigen-specific diabody produced in tobacco. FASEB J. 16 (2002) 408-410
23. Torres E., et al. Rice cell culture as an alternative production system for functional diagnostic and therapeutic antibodies. Transgenic Res. 8 (1999) 441-449
24. Stoger E., et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol. Biol. 42 (2000) 583-590
25. Perrin Y., et al. Transgenic pea seeds as bioreactors for the production of a single-chain Fv fragment (scFv) antibody used in cancer diagnosis and therapy. Molecular. Breed. 6 (2002) 345-352
26. Gavilondo J.V., and Larrick J.W. Antibody production technology in the millennium. Biotechniques 29 (2000) 128-145
27. Warzecha H., et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J. Virol. 77 (2003) 8702-8711
28. Franconi R., et al. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res. 62 (2002) 3654-3658
29. Massa S., et al. Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 25 (2007) 3018-3021
30. Varsani A., et al. Expression of human papillomavirus Type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch. Virol. 148 (2003) 1771-1786
31. Liu H.L., et al. Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants. Acta Biochim. Biophys. Sin. (Shanghai) 37 (2005) 153-158
32. Biemelt S., et al. Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic Plants. J. Virol. 77 (2003) 9211-9220
33. Verch T., et al. Immunization with a plant-produced colorectal cancer antigen. Cancer Immunol. Immunother. 53 (2004) 92-99
34. Borisjuk N.V., et al. Production of recombinant proteins in plant root exudates. Nat. Biotechnol. 17 (1999) 466-469
35. Komarnytsky S., et al. Production of recombinant proteins in tobacco guttation fluid. Plant Physiol. 124 (2002) 927-933
36. Park Y., and Cheong H. Expression and production of recombinant human interleukin-2 in potato plants. Protein Protein Express. Purif. 25 (2002) 160-165
37. Menassa R., et al. Subcellular targeting of human interleukin-10 in plants. J. Biotechnol. 108 (2004) 179-183
38. Gutiérrez-Ortega A., et al. Expression of a single-chain human interleukin-12 gene in transgenic tobacco plants and functional studies. Biotechnol. Bioeng. 85 (2004) 734-740
39. Turchinovich A.A., et al. Transgenic tobacco plants producing human interleukin-18. Dokl. Biochem. Biophys. 395 (2004) 104-107
40. Gomord V., et al. Glycosylation of Plant-made Pharmaceuticals. In: Fischer R., and Schillberg S. (Eds). Molecular farming: plant-made pharmaceuticals and technical proteins (2004), Wiley-VCH Verlag GmbH & Co. KgaA 233-250
41. Chargelegue D., et al. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res. 9 (2000) 187-194
42. Cárdaba B., et al. Genetic restrictions in olive pollen allergy. J. Allergy Clin. Immunol. 105 (2000) 292-298
43. Ma J.K., et al. The production of recombinant pharmaceutical proteins in plants. Nat. Rev. Genet. 10 (2003) 794-805
44. Cox K.M., et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat. Biotechnol. 24 (2006) 1591-1597
45. Franklin S.E., and Mayfield S.P. Recent developments in the production of human therapeutic proteins in eukaryotic algae. Expert Opin. Biol. Ther. 5 (2005) 225-235
46. Knäblein J., and McCaman M. Modern biopharmaceuticals - recombinant protein expression in transgenic plants. SCREENING - Trends in Drug Discovery 6 (2003) 33-35
47. Mison D., and Curling J. The Industrial Production Costs of Recombinant Therapeutic Proteins Expressed in Transgenic Corn. BioPharm. Int. 13 (2000) 48-54
48. Sparrow P.A., et al. Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals. Transgenic. Res. 16 (2007) 147-161
49. Pujol M., et al. An integral approach towards a practical application for a plant-made monoclonal antibody in vaccine purification. Vaccine 23 (2005) 1833-1837
50. Knäblein J., et al. Plantibodies for Human Therapeutic Use. BioWorld Europe 1 (2007) 14-17
51. Spök A. Molecular farming on the rise - GMO regulators still walking a tightrope. Trends Biotechnol. 25 (2007) 74-82